Abstract:In the present study, N -(1-(2-bromobenzoyl)-4-cyano-1 H -pyrazol-5-yl) halogenated benzamides (5a-h) were prepared and evaluated for their in vitro anticancer activity against three cancer cell lines, namely hepatic cancer (HepG-2), breast cancer (MCF-7) and colon cancer (HCT-116). The derivatives 5a - d and 5h revealed the most promising growth inhibition effect, with IC 50 values ranging from 0.005133±0.000042 to 0.022249±0.000069 μM, compared to doxorubicin, which had IC 50 values of 0.004635±0.000002, 0.004587±0.000029, and 0.004064±0.000002 μM respectively. The potential ADME properties of 5a-h were investigated using calculations. Compounds 5a-h have good oral bioavailability and gastrointestinal absorption but cannot penetrate the blood-brain barrier. According to ADME results, 5b has a tumorigenic and reproductive effect. Furthermore, the derivatives 5a, 5b, and 5d produced promising safety profiles on the WI-38 normal cell line with IC 50 values of 0.045374±0.002593, 0.115714±0.006732, and 0.058241±0.003411 μM, respectively, compared to doxorubicin, which had IC 50 value of 0.038234±0.00223 μM. Moreover, utilizing afatinib and sorafenib as positive controls, compounds 5a, 5b , and 5d were further assessed as in vitro multitargeting candidates towards EGFR WT , VEGFR-2, and B-RAF WT . For the purpose of figuring out potential ligand-protien interactions and stability, in silico molecular docking simulations against VEGFR-2, EGFR WT , and B-RAF WT were run. The results exhibited that compound 5b was the most potent compound, producing an inhibition effect on EGFR WT and B-RAF WT kinases that was approximately equipotent to that obtained by the reference drugs afatinib and sorafenib with IC 50 values of 0.000140±0.000009 and 0.000158±0.000009 μM, respectively (IC 50 Afatinib : 0.000086±0.000004, IC 50 Sorafenib : 0.000097±0.000006) The molecular docking study confirmed the biological result. Moreover, compound 5b arrested the HCT-116 cell cycle at the G1/S phase and showed a good early and late apoptotic induction effect within HCT-116 cells.

A pyrazolopyridine as a novel AhR signaling activator with anti-breast cancer properties in vitro and in vivo

Synthesis, In vitro and In silico Studies of Novel bis‐triazolopyridopyrimidines from Curcumin Analogues as Potential Aromatase Agents

Pharmacophore Modeling, 3D QSAR, Molecular Dynamics Studies and Virtual Screening on Pyrazolopyrimidines as anti-Breast Cancer Agents

Acetic Acid Mediated for One-Pot Synthesis of Novel Pyrazolyl s-Triazine Derivatives for the Targeted Therapy of Triple-Negative Breast Tumor Cells (MDA-MB-231) via EGFR/PI3K/AKT/mTOR Signaling Cascades

The Role of the Aryl Hydrocarbon Receptor (AhR) and Its Ligands in Breast Cancer

Synthesis, characterization and bioactivity of new pyridine-2(H)-one, nicotinonitrile, and furo[2,3-b]pyridine derivatives

(Z)-2-(3,4-Dichlorophenyl)-3-(1 H-Pyrrol-2-yl)Acrylonitrile Exhibits Selective Antitumor Activity in Breast Cancer Cell Lines via the Aryl Hydrocarbon Receptor Pathway

Synthesis, Anti-Cancer Activity, Cell Cycle Arrest, Apoptosis Induction, and Docking Study of Fused Benzo[h]chromeno[2,3-d]pyrimidine on Human Breast Cancer Cell Line MCF-7

Current scenario of pyrazole hybrids with anti-breast cancer therapeutic applications

Unveiling the anticancer potential of novel spirooxindole-tethered pyrazolopyridine derivatives

Design, synthesis, biological evaluation, in silico ADME prediction and molecular docking of pyrazole-benzamides as multitargeting protien kinase inhibitors

Unraveling the chemotherapeutic potential of taxifolin ruthenium-p-cymene complex in breast carcinoma: Insights into AhR signaling pathway in vitro and in vivo

Novel 1,3-Thiazole Analogues with Potent Activity against Breast Cancer: A Design, Synthesis, In Vitro, and In Silico Study

Synthesis of S-alkylated oxadiazole bearing imidazo[2,1-b]thiazole derivatives targeting breast cancer: In vitro cytotoxic evaluation and in vivo radioactive tracing studies

Convenient one-pot synthesis and biological evaluation of novel 3,5-dimethyl-1H-pyrazole-1-carbothiohydrazide derivatives as new anti-tumor agents against both liver carcinoma (HepG2) and lung carcinoma (A549) cell lines

Novel Pyrazole‐Chalcone Hybrids: Synthesis and Computational Insights Against Breast Cancer.

Towards a New Generation of Hormone Therapies: Design, Synthesis and Biological Evaluation of Novel 1,2,3-Triazoles as Estrogen-Positive Breast Cancer Therapeutics and Non-Steroidal Aromatase Inhibitors

Synthesis, In Vitro Evaluation and Molecular Docking Studies of Novel Thiophenyl Thiazolyl-Pyridine Hybrids as Potential Anticancer Agents

Molecular properties prediction, anticancer and anti-inflammatory activities of some pyrimido[1,2-b]pyridazin-2-one derivatives

Multi-targeted molecular docking, drug-likeness and ADMET studies of derivatives of few quinoline- and acridine-based FDA-approved drugs for anti-breast cancer activity

Design, synthesis and potent anti-pancreatic cancer activity of new pyrazole derivatives bearing chalcone, thiazole and thiadiazole moieties: gene expression, DNA fragmentation, cell cycle arrest and SAR